COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
The purpose of this study is to compare the efficacy of treatment with rosuvastatin with
 atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in
 subjects with metabolic syndrome.
Inclusion Criteria:

 -  Presence of 3 or more coronary heart disease risk factors as defined by the protocol.

 -  Fasting low density lipoprotein cholesterol level of > 130 mg/dL.

 -  Documented history of, or high risk of coronary heart disease or other established
 atherosclerotic disease.

 -  Not previously taken statins.

 Exclusion Criteria:

 -  The use of lipid lowering drugs or dietary supplements after Visit 1

 -  Active arterial disease eg Unstable angina, or recent arterial surgery

 -  Blood lipid levels above the limits defined in the protocol

 -  Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse